CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)

CLEOPATTRA

This trial is Coming soon
Registration number NCT07207811
This study aims to determine whether a new medication, NNC6019-0001, can lower the risk of heart-related complications in people diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that affects the heart. Participants will be randomly assigned to receive either NNC6019-0001 or a placebo, which contains no active drug. Throughout the study, all participants will continue their standard heart treatments as advised by their healthcare provider.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Cardiology program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof James Hare

Key inclusion data

Confirmed diagnosis of transthyretin cardiac amyloidosis (ATTR-CM). Please contact the cardiac amyloid team for further information: cardiacamyloid@alfred.org.au

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.